Why Should You Attend:
The rapid development of cell-based and related biological therapies for use in veterinary medicine has provided exciting new options for the safe and effective treatment of common veterinary diseases and conditions such as osteoarthritis, tendon strain injuries, suspensory desmitis, congestive heart failure and other commonly diagnosed diseases and injuries.
FDA’s Center for Veterinary Medicine (“CVM”) asserts primary and exclusive regulatory jurisdiction over veterinary regenerative products and their future commercialization in the U.S. Under CVM’s proposed regulatory approach, a veterinary regenerative product exceeding a hypothetical veterinary equivalent standard will be treated as a drug requiring FDA review and approval prior to marketing and sale.
This webinar will provide an introduction to FDA’s regulation of veterinary regenerative medicine and highlights the regulatory requirements that a biotech company needs to satisfy to commercialize a stem cell or other complex biotech product for animal use in the U.S. It will provide an introduction to veterinary stem cell therapy, an overview of the veterinary drug approval product, a summary of FDA’s potential reliance on human cellular regulations to regulate such products, and recommendations for industry on strategies for mitigating FDA enforcement risks.
Areas Covered in the Seminar:
Who Will Benefit:
Karl Nobert, is a food and drug regulatory attorney with the law firm of Squire Sanders in Washington, DC. He provides regulatory advice and counseling to domestic and international pharmaceutical, medical device and biotech companies on issues related to the U.S. Food and Drug Administration’s regulation of human and veterinary drugs, devices and biologics. He regularly assists clients with determining the regulatory status of proposed products and how such product may be regulated by FDA. He also specifically helps companies with the development of strategies for the marketing and sale of regenerative medicine products include cellular, tissue and gene therapies. He frequently presents and has published on such topics.
The rapid development of cell-based and related biological therapies in veterinary medicine has provided additional options for safe and effective alternatives to traditional drug products. Scientific evidence and study data show positive results for the treatment of tendon strain injuries, suspensory desmitis, arthritis, congestive heart failure and other commonly diagnosed diseases and injuries. In addition to the potential for a more functionally optimal repair, biological therapies are particularly attractive for use in performance horses because there are currently no applicable withholding requirements that might restrict subsequent participation in competitions. Biological therapies are also increasingly used for the treatment of musculoskeletal injuries in human athletes with several high-profile successes being covered by the mainstream media.
FDA’s Center for Veterinary Medicine (“CVM”) asserts primary and exclusive regulatory jurisdiction over veterinary regenerative products and their future commercialization in the U.S. Despite asserting such authority, CVM has neither adopted regulations nor published official guidance articulating its regulatory position on such products. However, the FDA is currently working on a document for publication that will publicly articulate its regulatory position on veterinary regenerative products. The Agency has yet to say however when it will be published.
All indications suggest that FDA will create a regulatory scheme modeled after its approach to the regulation of human cellular and tissue products. FDA’s position on the use of cell- and tissue-based therapeutic agents, including stem cells, in human medicine was released in 2006, and in the absence of regulatory guidance specific to veterinary products, this position can be used to predict FDA’s potential position on veterinary biologic and regenerative therapies, if and when regulatory oversight is applied to veterinary use. In human medicine, cell- and tissue-based therapies are termed “human cells, tissues, and cellular and tissue-based products”, or HCT/Ps, and are defined as “articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient”. This definition covers allografts of bone, ligament, skin, and dura mater, as well as stem cell therapies.
Under CVM’s current regulatory approach, a veterinary regenerative product exceeding a hypothetical veterinary equivalent Minimal Manipulation Standard will generally be treated as a new animal drug product requiring FDA approval prior to marketing and sale. Under that proposed regulatory approach, a drug v. non-drug distinction will be made on the level of processing used to manufacture the proposed product. There is however an argument that such therapies fall under the regulation of the practice of veterinary medicine, because of their autologous nature, and that product approval should not be required. It is unlikely however that the final regulatory approach will triumph in the end.
Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
6201 America Center Drive Suite 240, San Jose, CA 95002, USA
PAYMENT METHOD: 100% Secure Transaction